BioSpace News Archive

Merck and Ridgeback Biotherapeutics today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the refusal of the marketing authorization for LAGEVRIO™ (molnupiravir) for the treatment of certain adults who have been diagnosed with COVID-19 in the European Union (EU).

On February 20, 2023 , Porton Advanced Solutions Ltd. (Porton Advanced) and Yinjia ( Shanghai ) Biosciences Co., Ltd. (Yinjia Biosciences) announced a strategic partnership in developing core protein raw materials for cell and gene therapy (CGT) and test reagent products for quality control and evaluation systems to accelerate the development and commercialization of CGT.

Castle Biosciences, Inc. today announced that its chief financial officer, Frank Stokes, was named to Finance & Investing’s Top 25 CFOs of Houston list for 2023.

Precision BioSciences, Inc. today announced a promotion and organizational changes within the Company’s Senior Leadership Team (SLT).

Werewolf Therapeutics today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating WTX-330.

The U.S. Food and Drug Administration issued an emergency use authorization for the first over-the-counter at-home diagnostic test that can differentiate and detect influenza A and B, commonly known as the flu, and SARS-CoV-2, the virus that causes COVID-19.

Quanterix Corporation, a company fueling scientific discovery through ultrasensitive biomarker detection, announced it will host a conference call on Monday, March 6, 2023, to discuss its fourth quarter earnings and full year 2022 financial results.

Passage Bio, Inc. announced updated clinical data from Imagine-1, a Phase 1/2 study of PBGM01, a gene therapy for GM1 gangliosidosis (GM1), are being presented today at the 19th Annual WORLDSymposium™.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new data from the APeX-S and APeX-2 clinical trials which evaluated oral, once-daily ORLADEYO ® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE).

Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced long-term results from an updated integrated analysis of 39 patients with metachromatic leukodystrophy (MLD) treated with investigational OTL-200 in the clinical development program.